3053 related articles for article (PubMed ID: 7927369)
1. Proliferation, phenotype, and cytotoxicity of human lymphocytes isolated from lymph nodes invaded by melanoma cells.
Nakashima M; Janiszewska M; Steplewski Z; Watanabe T; Schuchter L; Koprowski H
Hybridoma; 1994 Jun; 13(3):241-6. PubMed ID: 7927369
[TBL] [Abstract][Full Text] [Related]
2. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.
Nakashima M; Watanabe T; Koprowski H; Schuchter L; Steplewski Z
Cell Immunol; 1994 Apr; 155(1):53-61. PubMed ID: 7513262
[TBL] [Abstract][Full Text] [Related]
3. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
Itoh K; Platsoucas CD; Balch CM
J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
[TBL] [Abstract][Full Text] [Related]
4. HLA-B-restricted, CD8+ cytolytic human T cell clones derived from a melanoma-invaded lymph node.
Nakashima M; Watanabe T; Koprowski H; Steplewski Z
Hybridoma; 1996 Apr; 15(2):147-54. PubMed ID: 8743295
[TBL] [Abstract][Full Text] [Related]
5. Cytokine combinations for induction of antigen-specific cytolytic T lymphocytes from peripheral blood lymphocytes.
Tsujitani S; Nakashima M; Watanabe T; Kaibara N; Koprowski H; Steplewski Z
Anticancer Res; 1995; 15(3):655-60. PubMed ID: 7645938
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes.
Arienti F; Sulé-Suso J; Melani C; Maccalli C; Belli F; Illeni MT; Anichini A; Cascinelli N; Colombo MP; Parmiani G
Hum Gene Ther; 1994 Sep; 5(9):1139-50. PubMed ID: 7833372
[TBL] [Abstract][Full Text] [Related]
7. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
10. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
11. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
Burns GF; Triglia T; Werkmeister JA
J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
[TBL] [Abstract][Full Text] [Related]
12. Major histocompatibility complex-unrestricted cytolytic activity of human T cells. Analysis of precursor frequency and effector phenotype.
Patel SS; Thiele DL; Lipsky PE
J Immunol; 1987 Dec; 139(11):3886-95. PubMed ID: 3500232
[TBL] [Abstract][Full Text] [Related]
13. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
14. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
15. Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro.
Gately MK; Wilson DE; Wong HL
J Immunol; 1986 Feb; 136(4):1274-82. PubMed ID: 2418110
[TBL] [Abstract][Full Text] [Related]
16. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
17. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
19. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures.
Spits H; Yssel H; Paliard X; Kastelein R; Figdor C; de Vries JE
J Immunol; 1988 Jul; 141(1):29-36. PubMed ID: 2454260
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
